Apixaban

Apixaban (CAS 503612-47-3), the factor Xa inhibitor anticoagulant marketed as Eliquis, is manufactured by Polpharma to EP standard with an eco-friendly process, no nitrosamine risk, and particle-size flexibility via micronization, supplied in crystalline Form N-1 with EU, Korean and US DMF readiness. It is used to reduce stroke risk in atrial fibrillation, prevent deep vein thrombosis after hip or knee replacement surgery, and treat DVT or pulmonary embolism. As the compound remains under supplementary protection certificate (SPC) patent protection in Poland, Polpharma manufactures and offers it strictly for regulatory-submission and R&D purposes or for export to non-EU countries, and buyers are responsible for confirming patent status in their own markets. Samples are available, and it is sold into markets across the Americas, Europe, Australasia, Asia, the Middle East and Africa.